Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03100474 · ClinicalTrials.gov registry record

Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:

A clinical trial of Parkinson's Disease and Essential Tremor, sponsored by InSightec.

Active
Registry status
500
Enrollment target
9
Study locations

NCT03100474: Active study of Parkinson's Disease and Essential Tremor, sponsored by InSightec.

NCT03100474 is a study of Parkinson's Disease and Essential Tremor that is active but no longer recruiting, run by InSightec. The registered enrollment target is 500 participants, below the 632-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (21% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03100474, a study of Parkinson's Disease and Essential Tremor, is active but no longer recruiting, sponsored by InSightec.

ACTIVE NOT RECRUITING
Registry status
500 participants
Enrollment target
9
Study locations

Study Summary

A global post approval study to collect safety and effectiveness data related to ExAblate Neuro for the treatment of certain disorders such as Essential Tremor, Parkinson's Movement Disorders, or Neuropathic Pain within the thalamus and/or pallidum.

Primary Outcome

CRST

Study Locations (9)

Other

  • Rambam Healthcare Campus - Haifa
  • Sheba Medical Center - Ramat Gan
  • Chang Bing Show Chwan Memorial Hospital - Chang-hua

California

  • Stanford University - Stanford

Maryland

  • University of Maryland - Baltimore

Pennsylvania

  • University of Pennsylvania - Philadelphia

Virginia

  • University of Virginia - Charlottesville

Washington

  • Swedish Neuroscience Institute - Seattle

Ontario

  • Sunnybrook - Toronto

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2016-12
Est. Completion 2026-06
InSightec

38 total trials

What the registry record for NCT03100474 still lists

NCT03100474 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 632-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (21% lower).

The record links to 4 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03100474 lists 9 locations in 7 states (Other, California, Maryland).

Frequently Asked Questions

What is clinical trial NCT03100474 about?

NCT03100474 is a clinical study titled "Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:". A global post approval study to collect safety and effectiveness data related to ExAblate Neuro for the treatment of certain disorders such as Essential Tremor, Parkinson's Movement Disorders, or Neuropathic Pain within the thalamus and/or pallidum.

What is the current status of trial NCT03100474?

This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2016-12. Estimated completion is 2026-06.

What conditions does trial NCT03100474 study?

This clinical trial studies the following conditions: Parkinson's Disease, Essential Tremor, Neuropathic Pain, Movement Disorders.

Who is sponsoring clinical trial NCT03100474?

This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03100474 being conducted?

This trial has 9 study locations across California, Maryland, Pennsylvania, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03100474's enrollment target sits among peer trials

500 18th of 158 higher than 141 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03100474, the US trial registry maintained by the National Library of Medicine. NCT03100474 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.